When he was announcing the PBS listing of one of these at-risk MS medicines late last year, having presumably been told that any price reduction would put it at risk, officials were probably well and truly in the process of manoeuvring the provider of another off-patent medicine brand into accepting an almost 50 per cent cut.
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
AbbVie records a 13-year streak as 'A Great Place to Work'
July 29, 2026 - - Latest News -
Helping to build Australia’s life sciences future at Brisbane’s innovation junction
July 29, 2026 - - Latest News -
AFT Pharmaceuticals sees significant opportunity in a diverse R&D pipeline
July 28, 2026 - - Latest News -
New research shows chronic pain is widespread and undertreated in Australia
July 28, 2026 - - Latest News -
Long-COVID still reshaping life for medically vulnerable Australians
July 28, 2026 - - Latest News -
Australians with rare diseases still waiting too long for access to treatments
July 28, 2026 - - Latest News -
TGA approves GSK's six‑monthly treatment for severe eosinophilic asthma and nasal polyps
July 28, 2026 - - Latest News

